NCT06086431

Brief Summary

Effect of perineurial dexamethasone and dexmedetomidine on erector spinal plane block duration for pediatric, idiopathic scoliosis surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2023

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 11, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 17, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

October 17, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 24, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 5, 2024

Completed
Last Updated

January 21, 2025

Status Verified

January 1, 2024

Enrollment Period

11 months

First QC Date

October 11, 2023

Last Update Submit

January 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • first need of opiate

    Time after surgery when the patient needs opiate for the first time

    48 hours

Secondary Outcomes (14)

  • Opioid consumption

    48 hours

  • Numerical Rating Scale [range 0:10]

    4 hours after surgery

  • Numerical Rating Scale [range 0:10]

    8 hours after surgery

  • Numerical Rating Scale [range 0:10]

    12 hours after surgery

  • Numerical Rating Scale [range 0:10]

    16 hours after surgery

  • +9 more secondary outcomes

Study Arms (3)

Placebo

PLACEBO COMPARATOR

0.2% ropivacaine for erector spinae plane block

Drug: 0.9% sodium chloride

Dexamethasone

ACTIVE COMPARATOR

0.2% ropivacaine + 0.1mg/kg Dexamethasone for erector spinae plane block

Drug: Dexamethasone

Dexmedetomidine

ACTIVE COMPARATOR

0.2% ropivacaine + 0.1ug/kg Dexmedetomidine for erector spinal plane block

Drug: Dexmedetomidine

Interventions

administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block

Also known as: placebo
Placebo

administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block

Dexamethasone

administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block

Dexmedetomidine

Eligibility Criteria

Age10 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • children scheduled for idiopathic scoliosis surgery
  • age \>10 and \<18 years

You may not qualify if:

  • age \< 10 years
  • age \< 18 years
  • infection at the site of the regional blockade
  • coagulation disorders
  • immunodeficiency
  • ASA= or \>4
  • steroid medication in regular use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland

Poznan, Wielkopolska, 61-545, Poland

Location

MeSH Terms

Conditions

Scoliosis

Interventions

Sodium ChlorideDexamethasoneDexmedetomidine

Condition Hierarchy (Ancestors)

Spinal CurvaturesSpinal DiseasesBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Tomasz Kotwicki, Prof.dr hab.

    Poznan University of Medical Sciences

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 11, 2023

First Posted

October 17, 2023

Study Start

October 17, 2023

Primary Completion

September 24, 2024

Study Completion

November 5, 2024

Last Updated

January 21, 2025

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations